FibroBiologics Statistics

Total Valuation

FibroBiologics has a market cap or net worth of $39.47 million. The enterprise value is $33.21 million.

Market Cap	39.47M
Enterprise Value	33.21M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, before market open.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroBiologics has 35.09 million shares outstanding. The number of shares has increased by 11.23% in one year.

Current Share Class	35.09M
Shares Outstanding	35.09M
Shares Change (YoY)	+11.23%
Shares Change (QoQ)	+2.44%
Owned by Insiders (%)	21.86%
Owned by Institutions (%)	16.29%
Float	25.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	13.94
P/TBV Ratio	14.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.57.

Current Ratio	1.23
Quick Ratio	1.17
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-833.67

Financial Efficiency

Return on equity (ROE) is -267.86% and return on invested capital (ROIC) is -93.17%.

Return on Equity (ROE)	-267.86%
Return on Assets (ROA)	-65.77%
Return on Invested Capital (ROIC)	-93.17%
Return on Capital Employed (ROCE)	-329.77%
Revenue Per Employee	n/a
Profits Per Employee	-$1.78M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.89% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-90.89%
50-Day Moving Average	1.86
200-Day Moving Average	3.91
Relative Strength Index (RSI)	32.20
Average Volume (20 Days)	524,795

Short Selling Information

The latest short interest is 1.80 million, so 5.14% of the outstanding shares have been sold short.

Short Interest	1.80M
Short Previous Month	2.50M
Short % of Shares Out	5.14%
Short % of Float	7.14%
Short Ratio (days to cover)	9.43

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-12.51M
Pretax Income	-19.47M
Net Income	-17.78M
EBITDA	-12.36M
EBIT	-12.51M
Earnings Per Share (EPS)	-$0.57

Full Income Statement

Balance Sheet

The company has $7.83 million in cash and $1.56 million in debt, giving a net cash position of $6.27 million or $0.18 per share.

Cash & Cash Equivalents	7.83M
Total Debt	1.56M
Net Cash	6.27M
Net Cash Per Share	$0.18
Equity (Book Value)	2.74M
Book Value Per Share	0.08
Working Capital	1.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$10.43 million and capital expenditures -$87,000, giving a free cash flow of -$10.52 million.

Operating Cash Flow	-10.43M
Capital Expenditures	-87,000
Free Cash Flow	-10.52M
FCF Per Share	-$0.30

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.23%
Shareholder Yield	-11.23%
Earnings Yield	-45.04%
FCF Yield	-26.64%

Analyst Forecast

The average price target for FibroBiologics is $13.00, which is 1,055.56% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.00
Price Target Difference	1,055.56%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-5.88%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1